AstraZeneca sees stock market value slump by more than £20bn after drug setback
- Center-left1
- Center1
- Center-right2
2 agency rewrites / co-publications detected
Summary
AstraZeneca sees stock market value slump by more than £20bn after drug setback. The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease. Wainua is a gene silencer that suppresses the production of abnormal proteins in the liver, which can affect tissues elsewhere in the body.
Cross-referenced from 4 sources.
Factual coreconfirmed by several independent voices
AstraZeneca sees stock market value slump by more than £20bn after drug setback.
reliability moderate2/4 sourcesThe FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease
reliability moderate2/2 sources
Reported detailssecondary facts, each attributed to its source
Wainua is a gene silencer that suppresses the production of abnormal proteins in the liver, which can affect tissues elsewhere in the body.
according to The Independent
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease
omitted byCentercovered byLeft sideRight sideAstraZeneca sees stock market value slump by more than £20bn after drug setback.
omitted byCentercovered byLeft sideRight side